Vyvo Achieves FDA Approval for Wearable Devices, Merging Blockchain Technology with Healthcare Innovation

0
334

 ​[[{“value”:”

SINGAPORE, SINGAPORE, May 14th, 2024, Chainwire

Vyvo Smart Chain, a HealthFi ecosystem that rewards health tracking through data monetization, today announced that Vyvo has received U.S. Food and Drug Administration (FDA) clearance for LifeWatch, the company’s innovative wearable device for health & wellness tracking. This achievement marks a significant leap forward in the convergence of blockchain technology and health monitoring.

Vyvo’s LifeWatch pioneers a new era in health and wellness. LifeWatch promotes a user-centric health monitoring model and leverages Decentralized Physical Infrastructure network (DePIN) technology to allow users to monetize their health data. This ensures privacy, anonymity, and full ownership and control over personal health data, empowering users to securely manage and monetize their information.

Fabio Galdi, Co-Founder and CEO of Vyvo, stated, “This approval marks a significant advancement in integrating blockchain technology into health and wellness. Our commitment is to innovation and user empowerment, and this FDA clearance positions us to continue challenging the current norms and lead a transformation in health solutions.”

Vyvo not only empowers users with advanced wellness monitoring tools but also fosters a secure and transparent ecosystem for health data, powered by blockchain technology. By continually pushing the boundaries of digital health management, Vyvo opens up new avenues for individuals to take charge of their well-being.

Vyvo’s wearable devices are available at helohealth.com. To learn more about VSC and earning rewards through health tracking, users can visit vyvo.com.

About Vyvo Smart Chain

Vyvo Smart Chain is a HealthFi ecosystem that rewards health tracking through data monetization on IoT devices. Vyvo makes it easy for people to understand and track their body stats, secure health data privacy and earn rewards for doing so while contributing to research into new drugs, developing treatments, and preventing the spread of diseases.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.

ContactMike Evansmike@multipliedhq.com

This article was originally published on Chainwire

“}]] 

Post Disclaimer

The information provided in our posts or blogs are for educational and informative purposes only. We do not guarantee the accuracy, completeness or suitability of the information. We do not provide financial or investment advice. Readers should always seek professional advice before making any financial or investment decisions based on the information provided in our content. We will not be held responsible for any losses, damages or consequences that may arise from relying on the information provided in our content.

LEAVE A REPLY

Please enter your comment!
Please enter your name here